Want to see LLY full AI Analyst Report?

Eli Lilly & Co (LLY) Stock Forecast & Price Target

23,279 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

18 Buy

2 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$1,396.61

▲(13.21% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $1,396.61 with a high forecast of $1,600.00 and a low forecast of $1,220.00. The average price target represents a 13.21% change from the last price of $1,233.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"726":"$726","1601":"$1,601","944.75":"$944.8","1163.5":"$1,163.5","1382.25":"$1,382.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1396.611111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.40K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.22K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[726,944.75,1163.5,1382.25,1601],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1160,1193.8461538461538,1227.6923076923076,1261.5384615384614,1295.3846153846155,1329.2307692307693,1363.076923076923,1396.923076923077,1430.7692307692307,1464.6153846153848,1498.4615384615386,1532.3076923076924,1566.1538461538462,{"y":1600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1160,1178.2008547008547,1196.4017094017095,1214.6025641025642,1232.8034188034187,1251.0042735042734,1269.2051282051282,1287.405982905983,1305.6068376068376,1323.8076923076924,1342.0085470085469,1360.2094017094016,1378.4102564102564,{"y":1396.611111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1160,1164.6153846153845,1169.2307692307693,1173.8461538461538,1178.4615384615386,1183.076923076923,1187.6923076923076,1192.3076923076924,1196.923076923077,1201.5384615384614,1206.1538461538462,1210.7692307692307,1215.3846153846155,{"y":1220,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":727.988,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":820.246,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":857.452,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1052.803,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1069.513,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1039.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1014.766,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":951.516,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":960.298,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1080.651,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1190.034,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1147.196,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1160,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,600

Average Price Target$1,397

Lowest Price Target$1,220

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chris Schott

J.P. Morgan

$1,400

Buy

13.48%

Upside

Reiterated

09/02/26

Eli Lilly Buy Rating Reiterated as Analyst Sees Multi‑Year Growth Upside, Maintains $1,400 December 2026 Price Target

Geoff Meacham

Citi

$1,600

Buy

29.70%

Upside

Reiterated

09/01/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)

Akash Tewari

Jefferies

$1,350→$1,440

Buy

16.73%

Upside

Reiterated

09/01/26

Jefferies Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

$1,400

Buy

13.48%

Upside

Reiterated

08/31/26

Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), Novartis (NVS)

Courtney Breen

Bernstein

$1,385

Buy

12.27%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Eli Lilly & Co (NYSE: LLY) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Emily Field

Barclays

$1,400

Buy

13.48%

Upside

Reiterated

08/31/26

Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Nico Chen

DBS

$1,550

Buy

25.64%

Upside

Reiterated

08/25/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Eli Lilly & Co (NYSE: LLY)

Jason Gerberry

Bank of America Securities

$1,344

Buy

8.94%

Upside

Reiterated

08/21/26

Eli Lilly Buy Rating Reiterated on Durable Incretin and Obesity Growth, Price Target Maintained at $1,344

Kerry Holford

Berenberg Bank

$1,135→$1,220

Hold

-1.11%

Downside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Ascendis Pharma (NASDAQ: ASND)

Srikripa Devarakonda

Truist Financial

$1,376

Buy

11.54%

Upside

Reiterated

08/11/26

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

$1,283→$1,367

Buy

10.81%

Upside

Reiterated

08/06/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

$1,347→$1,419

Buy

15.02%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,419 from $1,347 at Morgan StanleyEli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley

Louise Chen

Scotiabank

$1,300

Buy

5.38%

Upside

Reiterated

08/06/26

Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Carter Gould

Cantor Fitzgerald

$1,350→$1,410

Buy

14.29%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,410 from $1,350 at Cantor FitzgeraldEli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chris Schott

J.P. Morgan

$1,400

Buy

13.48%

Upside

Reiterated

09/02/26

Eli Lilly Buy Rating Reiterated as Analyst Sees Multi‑Year Growth Upside, Maintains $1,400 December 2026 Price Target

Geoff Meacham

Citi

$1,600

Buy

29.70%

Upside

Reiterated

09/01/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)

Akash Tewari

Jefferies

$1,350→$1,440

Buy

16.73%

Upside

Reiterated

09/01/26

Jefferies Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

$1,400

Buy

13.48%

Upside

Reiterated

08/31/26

Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), Novartis (NVS)

Courtney Breen

Bernstein

$1,385

Buy

12.27%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Eli Lilly & Co (NYSE: LLY) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Emily Field

Barclays

$1,400

Buy

13.48%

Upside

Reiterated

08/31/26

Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Nico Chen

DBS

$1,550

Buy

25.64%

Upside

Reiterated

08/25/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Eli Lilly & Co (NYSE: LLY)

Jason Gerberry

Bank of America Securities

$1,344

Buy

8.94%

Upside

Reiterated

08/21/26

Eli Lilly Buy Rating Reiterated on Durable Incretin and Obesity Growth, Price Target Maintained at $1,344

Kerry Holford

Berenberg Bank

$1,135→$1,220

Hold

-1.11%

Downside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Ascendis Pharma (NASDAQ: ASND)

Srikripa Devarakonda

Truist Financial

$1,376

Buy

11.54%

Upside

Reiterated

08/11/26

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

$1,283→$1,367

Buy

10.81%

Upside

Reiterated

08/06/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

$1,347→$1,419

Buy

15.02%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,419 from $1,347 at Morgan StanleyEli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley

Louise Chen

Scotiabank

$1,300

Buy

5.38%

Upside

Reiterated

08/06/26

Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Carter Gould

Cantor Fitzgerald

$1,350→$1,410

Buy

14.29%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,410 from $1,350 at Cantor FitzgeraldEli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

BLTEBelite Bio, Inc. ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

Geoff MeachamCiti

Success Rate

33/44 ratings generated profit

Average Return

+11.73%

Copying Geoff Meacham's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +11.73% per trade.

1 Year

Geoff MeachamCiti

Success Rate

42/44 ratings generated profit

Average Return

+42.00%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 95.45% of your transactions generating a profit, with an average return of +42.00% per trade.

2 Years

Geoff MeachamCiti

Success Rate

43/44 ratings generated profit

Average Return

+64.69%

Copying Geoff Meacham's trades and holding each position for 2 Years would result in 97.73% of your transactions generating a profit, with an average return of +64.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 52 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,396.61.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $9.85 with a range of $8.95 to $11.30. The previous quarter’s EPS was $8.38. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $22.16B with a range of $20.98B to $24.04B. The previous quarter’s sales results were $22.97B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,396.61.

What is LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 13.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LLY a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy which is based on 18 buy ratings, 2 hold ratings and 0 sell ratings.

What is Eli Lilly & Co’s price target?

The average price target for Eli Lilly & Co is 1,396.61. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,600.00 ,the lowest forecast is $1,220.00. The average price target represents 13.21% Increase from the current price of $1,233.66.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of LLY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts